Royalty Pharma (RPRX) Stock Price, News & Analysis

Company Overview

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to life sciences companies in exchange for rights to receive future royalty payments from commercialized or late-stage therapies. Rather than developing and marketing medicines itself, the company invests in pharmaceutical and biotechnology innovations and seeks to generate income from the resulting royalty streams.

Its portfolio is linked to a range of therapies across areas including oncology, immunology, neuroscience, rare diseases and other specialty markets. Royalty Pharma has held interests associated with medicines such as Imbruvica, Tysabri, Tremfya, Xtandi and Evrysdi, among others. The company’s royalty interests may be derived from products marketed in the United States and international markets.

Royalty Pharma was founded in 1996 by Pablo Legorreta and became a publicly traded company on the Nasdaq in 2020. Legorreta serves as the company’s chief executive officer. Through partnerships with biopharmaceutical companies, academic institutions and research organizations, Royalty Pharma aims to provide non-dilutive capital that can support drug development while obtaining rights to future payments from successful therapies.

Key Stats

• Today's Range: $57.97 to $58.96
• 50-Day Range: $55.67 to $63.96
• 52-Week Range: $34.63 to $64.38
• Volume: 7.10 million shs
• Average Volume: 3.06 million shs
• Market Capitalization: $33.59 billion
• P/E Ratio: 40.28
• Dividend Yield: 1.61%
• Price Target: $61.29
• Consensus Rating: Buy

Royalty Pharma Stock Analysis - MarketRank™

Royalty Pharma scored higher than 82% of companies evaluated by MarketBeat, and ranked 85th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Buy

Consensus Rating

Royalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Royalty Pharma is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Royalty Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3.95%

Earnings Growth

Earnings for Royalty Pharma are expected to grow by 3.95% in the coming year, from $5.32 to $5.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Royalty Pharma is 40.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Royalty Pharma is 40.28, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.21.

Price to Earnings Growth Ratio

Royalty Pharma has a PEG Ratio of 1.38. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Royalty Pharma has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.55% of the float of Royalty Pharma has been sold short.

Short Interest Ratio / Days to Cover

Royalty Pharma has a short interest ratio ("days to cover") of 5.05.

Change versus previous month

Short interest in Royalty Pharma has recently increased by 2.56%, indicating that investor sentiment is decreasing.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Royalty Pharma pays a meaningful dividend of 1.61%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Royalty Pharma has been increasing its dividend for 5 years.

Dividend Coverage

The dividend payout ratio of Royalty Pharma is 64.83%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Royalty Pharma will have a dividend payout ratio of 17.00% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.98

News Sentiment

Royalty Pharma has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Royalty Pharma this week, compared to 5 articles on an average week.

Search Interest

Only 8 people have searched for RPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

11 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Royalty Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,513,280.00 in company stock.

Percentage Held by Insiders

18.84% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Record date for 9/10 Dividend: 8/14/2026
• Ex-Dividend for 9/10 Dividend: 8/14/2026
• Dividend Payable: 9/10/2026
• Today: 9/20/2026
• Bank of America Global Healthcare Conference: 9/23/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:RPRX
• CIK: 1802768
• Web: www.royaltypharma.com
• Phone: 212-883-0200
• Fax: N/A
• Employees: 100
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Royalty Pharma: $61.29
• High Price Target: $68.00
• Low Price Target: $45.00
• Potential Upside/Downside: +4.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.45
• Trailing P/E Ratio: 40.28
• Forward P/E Ratio: 10.98
• P/E Growth: 1.38
• Net Income: $770.95 million
• Net Margins: 32.14%
• Pretax Margin: 53.11%
• Return on Equity: 30.01%
• Return on Assets: 14.91%

Debt

• Debt-to-Equity Ratio: 0.88
• Current Ratio: 2.80
• Quick Ratio: 2.80

Sales & Book Value

• Annual Sales: $2.54 billion
• Price / Sales: 13.24
• Cash Flow: $4.78 per share
• Price / Cash Flow: 12.23
• Book Value: $16.83 per share
• Price / Book: 3.47

Miscellaneous

• Outstanding Shares: 575,001,000
• Free Float: 466,671,000
• Market Cap: $33.59 billion
• Optionable: Optionable
• Beta: 0.44